Skip to content Skip to footer
Subscribe Now
bluebird Bio
NEWS

Carlyle & SK Capital to Acquire Bluebird Bio

Shots:Carlyle & SK Capital have entered into definitive agreement to acquire Bluebird Bio for $3/share in cash, delisting it from public market. Acquisition will fund Bluebird’s commercial delivery of gene therapies for SCD, β-thalassemia, & cerebral adrenoleukodystrophy, with closing expected in H1’25 As per the deal, Bluebird stockholders will get $3/share & contingent…
February 24, 2025

Read more

Viewpoints_Rich Colvin
VIEWPOINTS

PharmaShots Interview: bluebird bio’s Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy

In an interview with PharmaShots, Rich Colvin, M.D., Ph.D., Interim Chief Medical Officer at bluebird bio shares his views on the Skysona and its working on CALD patients.Shots:If granted marketing authorization, Skysona would be the first approved one-time gene therapy for CALD which is a rare neurogenerative disease with typically childhood onsetThe CHMP opinion…
June 4, 2021

Read more